Ben Millen is a senior analyst in finance and business development at Neurvati Neurosciences and GRIN Therapeutics, where he assesses strategic partnership and investment opportunities. He is a recent graduate of the Ross School of Business at the University of Michigan, where he concentrated in finance and strategy and interned in strategy consulting and investment evaluation at KPMG and Samlyn Capital.